Patents by Inventor Mingqing CAI

Mingqing CAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TIGIT ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20230183345
    Abstract: Provided is a separated antigen-binding protein. The antigen-binding protein comprises at least one CDR in a heavy chain variable region VH, and the VH comprises an amino acid sequence shown in SEQ ID NO: 55. Also provided are an anti-TIGIT antibody, and a preparation method and an application thereof. The antigen-binding protein can specifically bind with a TIGIT antigen to block the binding of TIGIT and a ligand thereof, and can be used for preparing drugs for preventing or treating TIGIT-related diseases.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 15, 2023
    Inventors: Haijia YU, Mingqing CAI, Xiaoyue WEI, Shi CHEN, Jianmei XIE, Xiangyang ZHU
  • BINDER AGAINST PROGRAMMED DEATH-LIGAND AND APPLICATION THEREOF
    Publication number: 20220089741
    Abstract: Provided is an anti-PD-L1 monoclonal antibody. The antibody can be used to prepare a drug for preventing or treating a disease related to PD-L1.
    Type: Application
    Filed: March 10, 2020
    Publication date: March 24, 2022
    Inventors: Haijia YU, Ling YU, Mingqing CAI, Xiangyang ZHU
  • ANTI-PD-L1/VEGF BIFUNCTIONAL ANTIBODY AND USE THEREOF
    Publication number: 20220002418
    Abstract: The present invention provides an anti-PD-L1/VEGF bispecific antibody and a use thereof. Specifically, the present invention provides a bifunctional antibody, comprising: (a) anti-PD-L1 antibody or element; and (b) an anti-VEGF antibody or element linked to the anti-PD-L1 antibody or element. The bifunctional antibody of the present invention can simultaneously bind to VEGF and PD-L1, thereby exerting a therapeutic effect on VEGF and PD-L1-positive tumor cells (especially malignant tumor cells).
    Type: Application
    Filed: March 31, 2020
    Publication date: January 6, 2022
    Inventors: Xiangyang ZHU, Fengxue ZHANG, Mingqing CAI, Lei ZHANG, Shi CHEN, Ling YU
  • Antibody targeting interleukin 17A and preparation method and application thereof
    Patent number: 10981983
    Abstract: The present invention provides an antibody targeted to interleukin 17A (IL-17A), preparation method and the use thereof. In particular, the invention provides a novel anti-IL-17A monoclonal antibody. The antibody of the present invention is capable of binding IL-17A antigen with high specificity, has high affinity and low immunogenicity, and is used for preparing a medicament for preventing or treating an IL-17A-related disease such as various inflammatory or autoimmune diseases.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 20, 2021
    Assignee: Huabo Biopharm (Shanghai) Co., Ltd.
    Inventors: Xiangyang Zhu, Mingqing Cai, Haijia Yu, Huifeng Jia, Ling Yu
  • ANTIBODY TARGETING INTERLEUKIN 17A AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20200071394
    Abstract: The present invention provides an antibody targeted to interleukin 17A (IL-17A), preparation method and the use thereof. In particular, the invention provides a novel anti-IL-17A monoclonal antibody. The antibody of the present invention is capable of binding IL-17A antigen with high specificity, has high affinity and low immunogenicity, and is used for preparing a medicament for preventing or treating an IL-17A-related disease such as various inflammatory or autoimmune diseases.
    Type: Application
    Filed: January 19, 2018
    Publication date: March 5, 2020
    Inventors: Xiangyang ZHU, Mingqing CAI, Haijia YU, Huifeng JIA, Ling YU
  • Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules
    Publication number: 20180362659
    Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.
    Type: Application
    Filed: August 20, 2018
    Publication date: December 20, 2018
    Inventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
  • Human bispecific EGFRvIII and CD3 antibody engaging molecules
    Patent number: 10053514
    Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: August 21, 2018
    Assignees: Duke University, The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health
    Inventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
  • Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules
    Publication number: 20160168263
    Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.
    Type: Application
    Filed: July 9, 2014
    Publication date: June 16, 2016
    Applicants: DUKE UNIVERSITY, THE GOVERNMENT OF THE U.S. AS REPRESENTED BY THE SECRETARY OF HEALTH
    Inventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
  • Bispecific EGFRvIII x CD3 antibody engaging molecules
    Patent number: 9249217
    Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 2, 2016
    Assignees: Secretary, DHHS, Duke University
    Inventors: Darell D. Bigner, Chien-Tsun Kuan, John H. Sampson, Mingqing Cai, Bryan D. Choi, Ira H. Pastan
  • BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
    Publication number: 20120189630
    Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents.
    Type: Application
    Filed: November 15, 2011
    Publication date: July 26, 2012
    Applicant: DUKE UNIVERSITY
    Inventors: Darell D. BIGNER, Chien-Tsun KUAN, John H. SAMPSON, Mingqing CAI, Bryan D. CHOI